Chanley Howell Weighs in on FTC’s Impersonation Rule, Fight Against AI Powered Fraud
April 8, 2024
Information Week
Foley & Lardner LLP partner Chanley Howell joined the Information Week panel discussion, “FTC’s Impersonation Rule and the Fight Against AI-Powered Fraud,” to assess the U.S. Federal Trade Commission’s new rule targeting impersonation fraud.
“While the rule is not limited to AI, it was a clear motivating factor behind the rule,” Howell explained. “It’s another brick in the wall of building the laws that relate to AI.”
Howell said he views the rule as a net positive as it offers additional guidance on how best to advise clients, though he cautioned that as the rule increases the visibility of this issue, companies will need to stay aware of their potential liabilities.
To see a video recording of the panel discussion, click here.
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.